XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 38,429 $ 24,401
Drug Product Revenue [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 8,480  
Drug Product Revenue [Member] | AstraZeneca Agreements [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 4,450  
Drug Product Revenue [Member] | Astellas Agreement    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized 4,030  
Drug Product Revenue [Member] | Astellas Agreement | Europe [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Consideration constrained related to drug product shipment 11,800  
Drug Product Revenue [Member] | API Shipment [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Drug product revenue recognized $ 4,000